RGNX
Regenxbio Inc
7.40$
+2.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.5% | 19.8% | 20.9% | 16.4% | 4.4% | 23.4% | 23.1% | 11.0% | 48.4% | 41.2% | 40.3% | 11.9% | |
| 83.5% | 80.2% | 79.1% | 83.6% | 95.6% | 76.6% | 76.9% | 89.0% | 51.6% | 58.8% | 59.7% | 88.1% | |
| 81.1% | 227.7% | 991.1% | 550.6% | 38.4% | 352.5% | 107.6% | 38.6% | 215.1% | 257.4% | 250.2% | 133.9% | |
| 62.9% | 157.0% | 514.1% | 262.0% | 16.9% | 147.1% | 41.3% | 16.9% | 75.7% | 98.1% | 91.9% | 48.6% | |
| 143.2% | 384.4% | 1,502.9% | 813.7% | 55.3% | 499.5% | 154.0% | 55.0% | 284.8% | 355.9% | 339.8% | 182.7% | |
| -60.2% | -304.9% | -1,423.8% | -730.2% | 40.3% | -422.9% | -77.1% | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% | |
| 5.2% | 0.3% | 0.0% | 0.0% | 0.0% | 304.3% | 0.5% | 5.6% | 20.6% | 7.6% | 15.2% | 26.4% | |
| -65.4% | -300.6% | -1,381.6% | -704.0% | 47.6% | -276.7% | -68.6% | 30.0% | -248.8% | -292.2% | -272.5% | -113.8% | |
| 4.8% | -0.8% | -9.5% | 6.6% | 1.9% | -7.8% | 3.4% | 2.9% | -0.1% | -0.2% | – | – | |
| -65.4% | -300.6% | -1,372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% | |
| -59.7% | -299.3% | -1,412.0% | -704.3% | 42.1% | -256.4% | -62.6% | 37.7% | -216.7% | -265.4% | -237.9% | -78.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.